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THE CURRENT LANDSCAPE OF BREAST DENSITY NOTIFICATION
Breast density is one of a number of independent risk factors for breast cancer.1 Having dense
breasts (heterogeneously dense or extremely dense) is prevalent in 40-50% of women in the breast
screening population,2 making it one of the most common risk factors for breast cancer. Separate
from this, having dense breasts also increases a woman’s risk of having a breast cancer missed on
mammography, meaning that it increases the risk of having an interval cancer diagnosed before the
next scheduled mammogram in screening participants.3 This is due to lower sensitivity of
mammography in women with dense breast tissue.4
Over the past decade breast density has been a major topic of international discussion among
women, physicians and policy-makers as a way to manage the risk of breast cancer.5 In the United
States (US) unprecedented legislation has been enacted in 38 states and the District of Columbia to
notify women about their breast density. Following on from this, in early 2019 the US Congress
passed national breast density legislation which proposes that the US Food and Drug Administration
ensures that all mammography facilities include breast density information in reports sent to
patients and their physicians.6 This legislation has been driven by a complex social phenomena,
largely stemming from industry interest, consumer advocacy groups demanding that women be
informed, and concerns about the burden of missed cancers.5,7
However, it could be argued that legislation to enforce notification of breast density before
protocols for its management exist, neglects the fundamental premise of evidence-based medicine.
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The current evidence to support widespread breast density notification at a population level is still
lacking and the balance between the benefits and harms for an individual woman as well as society
as a whole is far from clear. Furthermore, at present, there are no uniform recommendations
provided to women who are informed they have dense breasts in regards to supplemental
screening.
The legislation in the US has broad implications for other countries currently considering
implementing breast density notification through population-based breast screening programs.8 For
example, in Australia, breast density-specific legislation has not been implemented and the national
screening program, BreastScreen Australia, does not routinely provide this information to women as
national policy.9 However, BreastScreen’s individual state services are reconsidering their stances
given the recent developments in the US and growing pressure from key consumer advocacy groups,
including public messaging targeting women’s ‘right to know’ about this issue. Likewise, in the
United Kingdom and Canada there are now major advocacy groups and petitions promoting
national breast density notification, although their national screening committees recently
concluded against measuring breast density. Other countries across the world with populationbased screening programs are also having similar discussions and debates about how best to
proceed in this complex space.
WHERE IS THE EVIDENCE WEAK OR LACKING?
In an era of shared decision making in healthcare, notifying women of their breast density has wellintentioned goals to improve individual decision making.10 At this time however, the lack of evidence
underscores several concerns about implementing breast density notification, and these wellintentions might actually cause more harm than good. First and foremost is the uncertainty about
what women who have dense breasts can do to manage their risk of dying from breast cancer.
Although supplemental screening with imaging modalities such as ultrasound and MRI has been
shown to enhance cancer detection in women with dense breasts,11 the limitations of these
additional tests and the overall health benefit remain unclear.11 12 The long-term outcomes including
the effect on the rate of advanced breast cancers and mortality have not yet been adequately
assessed or reported.13 Moreover, the potential benefit from detection of additional cancers
through supplemental screening in women with dense breasts may not outweigh the associated
downsides including false-positive readings and the possibility of further overdiagnosis and
overtreatment of breast cancer.7 14 All of these can then lead to associated iatrogenic harms and
costs.15
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Secondly, breast density is measured on a continuum leading to difficulty in categorisation. It has
been shown that there is variability in what constitutes dense or non-dense breasts among readings
for an individual woman (reflecting reader and potential temporal variability), with 13-19% of
women being re-classified into a different density category on their subsequent screen.12 Variability
in classifying breast density exists within and between radiologists which can lead to confusion for
an individual woman. To reduce inconsistencies from readers, automated breast density
measurement has been introduced for density reporting however the evidence on how this predicts
cancer risk is still evolving.16 Because different automated density systems use different mechanisms
and algorithms this may also contribute to additional variation. The degree to which women with
dense breasts are at increased risk of breast cancer is also inconsistently measured in the evidence.
For example, some studies have compared women with ‘extremely dense’ and ‘heterogeneously
dense’ vs. women with ‘scattered fibroglandular density’ and ‘fatty’ breasts, whereas others only
compare the extreme categories (‘extremely dense’ vs. ‘fatty’ breasts). This adds to the overall
variation in the estimated magnitude of risk attributed to having dense breasts and poses the
question about how we inform women of these uncertainties.
And lastly, an often overlooked concern relates to the unique challenges with communicating
information about breast density and its risk to women. Along with the uncertainties discussed
above, breast density is a risk factor that is not readily modifiable, unlike other lifestyle risk factors
(e.g. post-menopausal obesity) that carry a similar risk for breast cancer.17 With the current
inconsistencies in notification information in the US, women’s knowledge, awareness and
understanding of density has been shown to be low and quite variable.18 19 Studies in the US
highlight areas of uncertainty, gaps in knowledge and unmet support needs from both women being
notified of their breast density as well as among physicians notifying the women.8 Furthermore, it
has been shown20 that health information materials designed to communicate about breast density
score poorly on readability and understandability formulae, and are written beyond average reading
and health literacy levels of the population. Therefore current materials are not meeting even basic
quality standards for the provision of health information.20
All of these concerns suggest that women and physicians may not be equipped with enough
evidence, information or resources to assess, interpret and discuss the benefits and harms of breast
density results on screening mammograms and make informed, shared and actionable decisions.20 21
Moreover, the challenges we have described around breast density notification cannot necessarily
be solved simply by providing more information to individual women and doctors.22 At the forefront
of all of this is the short- and long-term psychological effect this may have on women undergoing
routine screening. The immediate psychological consequences of breast density notification are
relatively unknown8 and to our knowledge there are no rigorous or long-term evaluation studies
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providing evidence on the impact of breast density information. Furthermore, from a population
health perspective, it remains unknown whether routine density notification would confer sufficient
benefit to balance or outweigh all additional harms and costs. This would be essential if such policy
was to be enacted through legislation.
MOVING FORWARD
We believe that it is imperative to have robust evidence about whether to communicate breast
density information to women and, if so, how best to do it. Before this happens there first needs to
be an assessment of the balance between the benefits and harms at the societal level. There is also a
need for better understanding of both the short- and long-term effect that breast density
notification has had on women in the US. Developing an appropriate strategy for whether to and for
who to inform, including how to effectively notify women and communicate the potential benefits
and harms of density information in other countries may still be feasible. This will take time, so for
now screening services and programs could contribute through carefully planned research which
assesses the impact of providing breast density information to women on both the societal and
individual level.
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